Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenues:
Total revenue	$ 28,895	$ 5,027	$ 9,481
Operating expenses:
Cost of revenues	(13,148)	(766)	(70)
Research and development expenses	(12,630)	(15,102)	(26,415)
Selling, general and administrative expenses	(51,645)	(55,285)	(62,485)
Total operating expenses	(77,423)	(71,153)	(88,970)
Loss from operations	(48,528)	(66,126)	(79,489)
Other income (expense):
Other income (expense), net	469	1,187	215
Interest income (expense), net	(901)	(1,649)	(3,389)
Loss on extinguishment of debt		(2,757)
Loss before income taxes	(48,960)	(69,345)	(82,663)
Income tax expense	(490)	(139)	(101)
Net loss	$ (49,450)	$ (69,484)	$ (82,764)
Loss per share
Basic ($ per share)	$ (1.14)	$ (5.41)	$ (11.15)
Diluted ($ per share)	$ (1.14)	$ (5.41)	$ (11.15)
Weighted average number of shares:
Basic (in shares)	43,349,461	12,845,089	7,419,948
Diluted (in shares)	43,349,461	12,845,089	7,419,948
Product revenue, net
Revenues:
Total revenue	$ 23,386	$ 108	$ 1,538
Collaboration revenue
Revenues:
Total revenue	3,830	2,756	6,210
Research premium and grant revenue
Revenues:
Total revenue	$ 1,679	$ 2,163	$ 1,733